Analysis of Conformational Determinants Underlying HSP90-Kinase Interaction
Open Access
- 2 July 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (7) , e68394
Abstract
The role of HSP90 in stabilization of oncogenic tyrosine kinases made it an attractive therapeutic target for treating cancer but the molecular basis underlying the interaction between the HSP90 chaperone and client kinases is not elucidated yet. Using kinase inhibitors we show that the inactive conformation of ERBB2 does not interact with HSP90 chaperone and is thus not amenable to degradation upon HSP90 inhibitor treatment, while active ERBB2 kinase conformation promotes interaction with the HSP90 machinery and thus is degraded upon HSP90 inhibitor treatment. Interestingly, the kinase-chaperone interaction is disrupted in case of BCR-ABL and FLT3-ITD when bound to inhibitors irrespective of whether they block the kinase in an active or inactive conformation and thus our results indicate that the stability of the active kinase conformation varies between different kinases.Keywords
This publication has 29 references indexed in Scilit:
- Differential Sensitivity of ERBB2 Kinase Domain Mutations towards LapatinibPLOS ONE, 2011
- Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing CellsPLOS ONE, 2011
- Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2ABlood, 2011
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 ProteinJournal of Biological Chemistry, 2011
- Novel mutant-selective EGFR kinase inhibitors against EGFR T790MNature, 2009
- Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutationHaematologica, 2008
- Solution Conformations and Dynamics of ABL Kinase-Inhibitor Complexes Determined by NMR Substantiate the Different Binding Modes of Imatinib/Nilotinib and DasatinibJournal of Biological Chemistry, 2008
- Short Preoperative Treatment With Erlotinib Inhibits Tumor Cell Proliferation in Hormone Receptor–Positive Breast CancersJournal of Clinical Oncology, 2008
- Oncogenic Mutations Reduce the Stability of Src KinaseJournal of Molecular Biology, 2004
- Regulation of the Src Family Kinase Lck by Hsp90 and UbiquitinationMolecular and Cellular Biology, 2004